Keros Therapeutics Inc Forecast, price target & analysts
Keros Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Keros Therapeutics Inc Classifications & Recommendation:
Keros Therapeutics Inc Price Target
| Target Price | $33.55 |
| Price | $11.01 |
| Potential |
204.68%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target Keros Therapeutics Inc 2026 .
The average Keros Therapeutics Inc target price is $33.55.
This is
204.68%
register free of charge
$76.00
590.28%
register free of charge
$15.00
36.24%
register free of charge
|
|
| A rating was issued by 14 analysts: 9 Analysts recommend Keros Therapeutics Inc to buy, 5 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Keros Therapeutics Inc stock has an average upside potential 2026 of
204.68%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 3.55 | 1.34 |
| 2,266.67% | 62.25% | |
| EBITDA Margin | -5,904.23% | -16,709.82% |
| 94.76% | 183.01% | |
| Net Margin | -5,711.27% | -14,328.68% |
| 95.94% | 150.88% |
10 Analysts have issued a sales forecast Keros Therapeutics Inc 2025 . The average Keros Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Keros Therapeutics Inc 2025 . The average Keros Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $-210m | 23.93% |
|---|---|---|
| 2025 |
$-224m
6.83%
Unlock
|
|
EBITDA Margin
| 2024 | -5,904.23% | 94.76% |
|---|---|---|
| 2025 |
-16,709.82%
183.01%
Unlock
|
|
6 Keros Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Keros Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -5.00 | -4.74 |
| 3.85% | 5.20% | |
| P/E | negative | |
| EV/Sales | negative |
6 Analysts have issued a Keros Therapeutics Inc forecast for earnings per share. The average Keros Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Keros Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Keros Therapeutics Inc...
Current Keros Therapeutics Inc Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Feb 27 2025 |
| Wells Fargo | Locked ➜ Locked | Locked | Feb 27 2025 |
| Cantor Fitzgerald | Locked ➜ Locked | Locked | Jan 21 2025 |
| Wedbush | Locked ➜ Locked | Locked | Jan 17 2025 |
| Piper Sandler | Locked ➜ Locked | Locked | Jan 17 2025 |
| Guggenheim | Locked ➜ Locked | Locked | Jan 17 2025 |
| Oppenheimer | Locked ➜ Locked | Locked | Jan 16 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Feb 27 2025 |
|
Locked
Wells Fargo: Locked ➜ Locked
|
Feb 27 2025 |
|
Locked
Cantor Fitzgerald: Locked ➜ Locked
|
Jan 21 2025 |
|
Locked
Wedbush: Locked ➜ Locked
|
Jan 17 2025 |
|
Locked
Piper Sandler: Locked ➜ Locked
|
Jan 17 2025 |
|
Locked
Guggenheim: Locked ➜ Locked
|
Jan 17 2025 |
|
Locked
Oppenheimer: Locked ➜ Locked
|
Jan 16 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
